<p>Cogent Biosciences, Inc.（納斯達克代碼：COGT - 免費報告）- Wedbush 的分析師在 8 月 5 日星期二向投資者發佈的報告中下調了對 Cogent Biosciences 2025 財年的每股收益預期。Wedbush 分析師 D. Nierengarten 現在預計該科技公司將發佈每股收益（$2.21），低於之前的預期（$1.49）。Wedbush 目前對該股票的評級為 “中性”，目標價為 10.00 美元。市場普遍預計 Cogent Biosciences 當前全年的每股收益為（$2.42）。</p>
<p>其他幾家券商最近也發佈了關於 COGT 的報告。HC Wainwright 將 Cogent Biosciences 的目標價從 22.00 美元下調至 21.00 美元，並在週三的報告中對該公司給予 “買入” 評級。Needham &amp; Company LLC 在 6 月 17 日星期二的研究報告中重申了對 Cogent Biosciences 的 “持有” 評級。Jefferies Financial Group 在 7 月 7 日星期一的報告中將 Cogent Biosciences 的目標價從 23.00 美元上調至 28.00 美元，並給予該股票 “買入” 評級。Guggenheim 在 7 月 8 日星期二的報告中重申了 “買入” 評級，並將 Cogent Biosciences 的目標價設定為 17.00 美元。最後，花旗集團在 7 月 18 日星期五的報告中將 Cogent Biosciences 的目標價從 15.00 美元上調至 22.00 美元，並給予該股票 “買入” 評級。三位研究分析師對該股票給予了持有評級，七位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat 的數據，Cogent Biosciences 目前的共識評級為 “適度買入”，平均目標價為 18.70 美元。</p>
<p>獲取 <strong>Cogent Biosciences</strong> 的提醒：</p>
<p><strong>查看我們對 Cogent Biosciences 的最新股票分析</strong></p>
<h2>Cogent Biosciences 股票上漲 1.6%</h2>
<p>COGT 股票在週五上漲 0.18 美元，達到 11.04 美元。該公司的交易量為 87,926 股，而其平均交易量為 2,009,252 股。該公司的 50 日移動平均線為 9.13 美元，200 日移動平均線為 7.35 美元。Cogent Biosciences 的年低為 3.72 美元，年高為 12.97 美元。該股票的市值為 12.6 億美元，市盈率為-6.21，貝塔值為 0.36。</p>
<p>Cogent Biosciences（納斯達克代碼：COGT - 獲取免費報告）最近在 8 月 5 日星期二發佈了季度收益數據。該科技公司報告的季度每股收益為（$0.53），超出市場普遍預期的（$0.55）0.02 美元。</p>
<h2>機構投資者對 Cogent Biosciences 的看法</h2>
<p>機構投資者和對沖基金最近買賣了該股票的股份。ProShare Advisors LLC 在第二季度將其在 Cogent Biosciences 的股份增加了 4.1%。ProShare Advisors LLC 現在擁有 26,021 股該科技公司的股票，價值 187,000 美元，此前在此期間購買了 1,020 股。Corton Capital Inc.在第二季度將其在 Cogent Biosciences 的股份增加了 6.4%。Corton Capital Inc.現在擁有 17,438 股該科技公司的股票，價值 125,000 美元，此前在此期間購買了 1,046 股。Balyasny Asset Management L.P.在第四季度將其在 Cogent Biosciences 的股份增加了 8.8%。Balyasny Asset Management L.P.現在擁有 20,805 股該科技公司的股票，價值 162,000 美元，此前在此期間購買了 1,687 股。49 Wealth Management LLC 在第二季度將其在 Cogent Biosciences 的股份增加了 19.0%。49 Wealth Management LLC 現在擁有 15,508 股該科技公司的股票，價值 111,000 美元，此前在上個季度購買了 2,476 股。最後，亞利桑那州退休系統在第一季度將其在 Cogent Biosciences 的股份增加了 18.0%。亞利桑那州退休系統現在擁有 20,567 股該科技公司的股票，價值 123,000 美元，此前在上個季度購買了 3,142 股。</p>
<h2>內部買賣</h2>
<p>在相關消息中，董事 Fairmount Funds Management Llc 在 7 月 10 日星期四的交易中購買了 2,777,777 股該公司的股票。這些股票的平均購買價格為每股 9.00 美元，總交易額為 24,999,993.00 美元。收購完成後，該董事直接持有該公司 9,003,418 股股票，價值 81,030,762 美元。這筆交易代表了他們持股比例的 44.62% 的增加。該收購在向 SEC 的法律文件中披露，可以通過此鏈接訪問。公司內部人士持有該公司 7.29% 的股份。</p>
<h2>Cogent Biosciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Cogent Biosciences, Inc.是一家生物技術公司，專注於開發針對基因定義疾病的精準療法。其主要產品候選包括 bezuclastinib（CGT9486），這是一種選擇性酪氨酸激酶抑制劑，旨在針對 KIT 受體酪氨酸激酶中的突變，包括驅動系統性肥大細胞增生的 KIT D816V 突變，以及在晚期胃腸道間質瘤患者中發現的 KIT 外顯子 17 中的其他突變。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Cogent Biosciences 更好</li>
<li>三隻可以升級您投資組合的家居改善股票</li>
<li>為什麼 Axon 的 16% 激增預示着公共安全技術的新紀元</li>
<li>什麼是日經 225 指數？</li>
<li>DraftKings 發佈創紀錄季度，瞄準盈利</li>
<li>什麼是國債？</li>
<li>亞馬遜在 IonQ 中獲得股權投資——有什麼潛在收益？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09HVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09HVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Cogent Biosciences 嗎？</h2>
<p>在你考慮 Cogent Biosciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前立即購買……而 Cogent Biosciences 並不在名單上。</p>
<p>雖然 Cogent Biosciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

COGT

<p>Wedbush 分析師將 Cogent Biosciences (NASDAQ:COGT) 的 2025 財年每股收益預期從 ($1.49) 下調至 ($2.21)。當前的市場共識預期為每股 ($2.42)。Wedbush 維持 “中性” 評級，目標價為 $10.00。其他券商的評級各不相同，目標價範圍在 $17.00 到 $28.00 之間。COGT 股票最近交易價格為 $11.04，上漲 1.6%。該公司在上個季度報告的每股收益為 ($0.53)，超出預期。內部人士的買入使持股比例增加了 44.62%</p>

<p>Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Analysts at Wedbush cut their FY2025 earnings per share estimates for Cogent Biosciences in a note issued to investors on Tuesday, August 5th. Wedbush analyst D. Nierengarten now anticipates that the technology company will post earnings of ($2.21) per share for the year, down from their previous estimate of ($1.49). Wedbush currently has a &#34;Neutral&#34; rating and a $10.00 price target on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share.</p>
<div class="lb-trans"><p>Cogent Biosciences, Inc.（納斯達克代碼：COGT - 免費報告）- Wedbush 的分析師在 8 月 5 日星期二向投資者發佈的報告中下調了對 Cogent Biosciences 2025 財年的每股收益預期。Wedbush 分析師 D. Nierengarten 現在預計該科技公司將發佈每股收益（$2.21），低於之前的預期（$1.49）。Wedbush 目前對該股票的評級為 “中性”，目標價為 10.00 美元。市場普遍預計 Cogent Biosciences 當前全年的每股收益為（$2.42）。</p>
</div><p>Several other brokerages also recently issued reports on COGT. HC Wainwright lowered their price target on shares of Cogent Biosciences from $22.00 to $21.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday. Needham &amp; Company LLC reiterated a &#34;hold&#34; rating on shares of Cogent Biosciences in a research report on Tuesday, June 17th. Jefferies Financial Group lifted their target price on Cogent Biosciences from $23.00 to $28.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, July 7th. Guggenheim restated a &#34;buy&#34; rating and set a $17.00 price target on shares of Cogent Biosciences in a report on Tuesday, July 8th. Finally, Citigroup raised their price target on shares of Cogent Biosciences from $15.00 to $22.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 18th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Cogent Biosciences presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $18.70.</p>
<div class="lb-trans"><p>其他幾家券商最近也發佈了關於 COGT 的報告。HC Wainwright 將 Cogent Biosciences 的目標價從 22.00 美元下調至 21.00 美元，並在週三的報告中對該公司給予 “買入” 評級。Needham &amp; Company LLC 在 6 月 17 日星期二的研究報告中重申了對 Cogent Biosciences 的 “持有” 評級。Jefferies Financial Group 在 7 月 7 日星期一的報告中將 Cogent Biosciences 的目標價從 23.00 美元上調至 28.00 美元，並給予該股票 “買入” 評級。Guggenheim 在 7 月 8 日星期二的報告中重申了 “買入” 評級，並將 Cogent Biosciences 的目標價設定為 17.00 美元。最後，花旗集團在 7 月 18 日星期五的報告中將 Cogent Biosciences 的目標價從 15.00 美元上調至 22.00 美元，並給予該股票 “買入” 評級。三位研究分析師對該股票給予了持有評級，七位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat 的數據，Cogent Biosciences 目前的共識評級為 “適度買入”，平均目標價為 18.70 美元。</p>
</div><p>Get <strong>Cogent Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cogent Biosciences</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Cogent Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Cogent Biosciences 的最新股票分析</strong></p>
</div><h2>Cogent Biosciences Stock Up 1.6%</h2>
<div class="lb-trans"><h2>Cogent Biosciences 股票上漲 1.6%</h2>
</div><p>Shares of COGT stock traded up $0.18 on Friday, reaching $11.04. The company had a trading volume of 87,926 shares, compared to its average volume of 2,009,252. The business's 50-day moving average is $9.13 and its 200 day moving average is $7.35. Cogent Biosciences has a one year low of $3.72 and a one year high of $12.97. The stock has a market capitalization of $1.26 billion, a PE ratio of -6.21 and a beta of 0.36.</p>
<div class="lb-trans"><p>COGT 股票在週五上漲 0.18 美元，達到 11.04 美元。該公司的交易量為 87,926 股，而其平均交易量為 2,009,252 股。該公司的 50 日移動平均線為 9.13 美元，200 日移動平均線為 7.35 美元。Cogent Biosciences 的年低為 3.72 美元，年高為 12.97 美元。該股票的市值為 12.6 億美元，市盈率為-6.21，貝塔值為 0.36。</p>
</div><p>Cogent Biosciences (NASDAQ:COGT - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The technology company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.02.</p>
<div class="lb-trans"><p>Cogent Biosciences（納斯達克代碼：COGT - 獲取免費報告）最近在 8 月 5 日星期二發佈了季度收益數據。該科技公司報告的季度每股收益為（$0.53），超出市場普遍預期的（$0.55）0.02 美元。</p>
</div><h2>Institutional Investors Weigh In On Cogent Biosciences</h2>
<div class="lb-trans"><h2>機構投資者對 Cogent Biosciences 的看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the stock. ProShare Advisors LLC grew its stake in Cogent Biosciences by 4.1% in the 2nd quarter. ProShare Advisors LLC now owns 26,021 shares of the technology company's stock valued at $187,000 after purchasing an additional 1,020 shares during the period. Corton Capital Inc. raised its stake in shares of Cogent Biosciences by 6.4% during the 2nd quarter. Corton Capital Inc. now owns 17,438 shares of the technology company's stock valued at $125,000 after purchasing an additional 1,046 shares during the period. Balyasny Asset Management L.P. increased its position in shares of Cogent Biosciences by 8.8% during the fourth quarter. Balyasny Asset Management L.P. now owns 20,805 shares of the technology company's stock valued at $162,000 after buying an additional 1,687 shares during the period. 49 Wealth Management LLC lifted its stake in Cogent Biosciences by 19.0% in the 2nd quarter. 49 Wealth Management LLC now owns 15,508 shares of the technology company's stock worth $111,000 after purchasing an additional 2,476 shares in the last quarter. Finally, Arizona State Retirement System raised its position in shares of Cogent Biosciences by 18.0% in the first quarter. Arizona State Retirement System now owns 20,567 shares of the technology company's stock worth $123,000 after buying an additional 3,142 shares in the last quarter.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近買賣了該股票的股份。ProShare Advisors LLC 在第二季度將其在 Cogent Biosciences 的股份增加了 4.1%。ProShare Advisors LLC 現在擁有 26,021 股該科技公司的股票，價值 187,000 美元，此前在此期間購買了 1,020 股。Corton Capital Inc.在第二季度將其在 Cogent Biosciences 的股份增加了 6.4%。Corton Capital Inc.現在擁有 17,438 股該科技公司的股票，價值 125,000 美元，此前在此期間購買了 1,046 股。Balyasny Asset Management L.P.在第四季度將其在 Cogent Biosciences 的股份增加了 8.8%。Balyasny Asset Management L.P.現在擁有 20,805 股該科技公司的股票，價值 162,000 美元，此前在此期間購買了 1,687 股。49 Wealth Management LLC 在第二季度將其在 Cogent Biosciences 的股份增加了 19.0%。49 Wealth Management LLC 現在擁有 15,508 股該科技公司的股票，價值 111,000 美元，此前在上個季度購買了 2,476 股。最後，亞利桑那州退休系統在第一季度將其在 Cogent Biosciences 的股份增加了 18.0%。亞利桑那州退休系統現在擁有 20,567 股該科技公司的股票，價值 123,000 美元，此前在上個季度購買了 3,142 股。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In related news, Director Fairmount Funds Management Llc bought 2,777,777 shares of the company's stock in a transaction dated Thursday, July 10th. The shares were bought at an average price of $9.00 per share, for a total transaction of $24,999,993.00. Following the completion of the acquisition, the director directly owned 9,003,418 shares of the company's stock, valued at $81,030,762. This trade represents a 44.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 7.29% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，董事 Fairmount Funds Management Llc 在 7 月 10 日星期四的交易中購買了 2,777,777 股該公司的股票。這些股票的平均購買價格為每股 9.00 美元，總交易額為 24,999,993.00 美元。收購完成後，該董事直接持有該公司 9,003,418 股股票，價值 81,030,762 美元。這筆交易代表了他們持股比例的 44.62% 的增加。該收購在向 SEC 的法律文件中披露，可以通過此鏈接訪問。公司內部人士持有該公司 7.29% 的股份。</p>
</div><h2>Cogent Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Cogent Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.</p>
<div class="lb-trans"><p>Cogent Biosciences, Inc.是一家生物技術公司，專注於開發針對基因定義疾病的精準療法。其主要產品候選包括 bezuclastinib（CGT9486），這是一種選擇性酪氨酸激酶抑制劑，旨在針對 KIT 受體酪氨酸激酶中的突變，包括驅動系統性肥大細胞增生的 KIT D816V 突變，以及在晚期胃腸道間質瘤患者中發現的 KIT 外顯子 17 中的其他突變。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Cogent Biosciences</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Why Axon's 16% Surge Signals a New Era in Public Safety Tech</li>
<li>What is the Nikkei 225 index?</li>
<li>DraftKings Posts Record Quarter, Eyes Profitability</li>
<li>What Are Treasury Bonds?</li>
<li>Amazon Takes an Equity Stake in IonQ—Any Upside Potential?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Cogent Biosciences 更好</li>
<li>三隻可以升級您投資組合的家居改善股票</li>
<li>為什麼 Axon 的 16% 激增預示着公共安全技術的新紀元</li>
<li>什麼是日經 225 指數？</li>
<li>DraftKings 發佈創紀錄季度，瞄準盈利</li>
<li>什麼是國債？</li>
<li>亞馬遜在 IonQ 中獲得股權投資——有什麼潛在收益？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09HVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=COGT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cogent Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Cogent Biosciences 嗎？</h2>
</div><p>Before you consider Cogent Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Cogent Biosciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前立即購買……而 Cogent Biosciences 並不在名單上。</p>
</div><p>While Cogent Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cogent Biosciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Wedbush 對 Cogent Biosciences 2025 財年收益的展望持悲觀態度